The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: updated results from the tofacitinib ulcerative colitis clinical programme

被引：0
|
作者：
Sands, B. E. [1 ]
Taub, P. R. [2 ]
Feagan, B. G. [3 ]
Armuzzi, A. [4 ]
Damiao, A. O. [5 ]
Lawendy, N. [6 ]
Solano, G. [7 ]
Kwok, K. [8 ]
Woolcott, J. [6 ]
Salese, L. [6 ]
Su, C. [6 ]
机构：
[1] Icahn Sch Med Mt Sinai, Dr Henry D Janowitz Div Gastroenterol, New York, NY 10029 USA
[2] Univ Calif San Diego, Sch Med, Div Cardiovasc Med, La Jolla, CA USA
[3] Western Univ, Robarts Clin Trials, London, ON, Canada
[4] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Gemelli IRCCS, IBD Unit, Rome, Italy
[5] Univ Sao Paulo, Dept Gastroenterol, Sao Paulo, Brazil
[6] Pfizer Inc, Collegeville, PA USA
[7] Pfizer Inc, San Jose, Costa Rica
[8] Pfizer Inc, New York, NY USA
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P684
引用
收藏
页码：S557 / S558
页数：2
相关论文
共 50 条
  • [1] The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: results from the tofacitinib ulcerative colitis clinical programme
    Sands, B. E.
    Taub, P. R.
    Feagan, B. G.
    Armuzzi, A.
    Friedman, G. S.
    Moscariello, M.
    Lawendy, N.
    Pedersen, R. D.
    Chan, G.
    Nduaka, C. I.
    Quirk, D.
    Salese, L.
    Su, C.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S23 - S23
  • [2] THE EFFECT OF TOFACITINIB ON SERUM LIPIDS AND CARDIOVASCULAR SAFETY IN PATIENTS WITH ULCERATIVE COLITIS - UPDATED RESULTS FROM THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAM
    Sands, Bruce E.
    Taub, Pam R.
    Feagan, Brian G.
    Armuzzi, Alessandro
    Damiao, Aderson O.
    Lawendy, Nervin
    Solano, Gaston
    Kwok, Kenneth
    Woolcott, John
    Salese, Leonardo
    Su, Chinyu
    GASTROENTEROLOGY, 2020, 158 (06) : S1190 - S1190
  • [3] THE EFFECT OF TOFACITINIB ON SERUM LIPIDS AND CARDIOVASCULAR SAFETY IN PATIENTS WITH ULCERATIVE COLITIS - RESULTS FROM THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAM
    Sands, Bruce E.
    Taub, Pam R.
    Feagan, Brian G.
    Armuzzi, Alessandro
    Friedman, Gary S.
    Moscariello, Michele
    Lawendy, Nervin
    Pedersen, Ronald D.
    Chan, Gary
    Nduaka, Chudy I.
    Quirk, Daniel
    Salese, Leonardo
    Su, Chinyu
    GASTROENTEROLOGY, 2018, 154 (06) : S380 - S380
  • [4] THE EFFECT OF TOFACITINIB ON SERUM LIPIDS AND CARDIOVASCULAR SAFETY IN PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE TOFACITINIB OCTAVE ULCERATIVE COLITIS CLINICAL PROGRAM
    Vermeire, Severine
    Armuzzi, Alessandro
    Kwok, Kenneth K.
    Lawendy, Nerrvin
    Woolcott, John
    Salese, Leonardo
    Su, Chinyu
    Hudesman, David
    GASTROENTEROLOGY, 2021, 160 (06) : S353 - S353
  • [5] Tofacitinib for the Treatment of Ulcerative Colitis: An Updated Analysis of Infection Rates in the Tofacitinib Ulcerative Colitis Clinical Program
    Winthrop, Kevin L.
    Loftus, Edward V., Jr.
    Baumgart, Daniel C.
    Hart, Ailsa
    Alharbi, Othman R.
    Salese, Leonardo
    Lawendy, Nervin
    Mundayat, Rajiv
    Su, Chinyu
    Reinisch, Walter
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S323 - S323
  • [6] Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme
    Winthrop, Kevin L.
    Loftus, Edward V. Jr Jr
    Baumgart, Daniel C.
    Reinisch, Walter
    Nduaka, Chudy, I
    Lawendy, Nervin
    Chan, Gary
    Mundayat, Rajiv
    Friedman, Gary S.
    Salese, Leonardo
    Thorpe, Andrew J.
    Su, Chinyu
    JOURNAL OF CROHNS & COLITIS, 2021, 15 (06): : 914 - 929
  • [7] Tofacitinib for the treatment of Ulcerative Colitis: Analysis of malignancy rates from the Ulcerative Colitis clinical programme
    Ungaro, R. C.
    Ciorba, M. A.
    Rogler, G.
    Sharara, A. I.
    Sunna, N.
    Connelly, S. B.
    Mundayat, R.
    Lawendy, N.
    Panes, J.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S357 - S359
  • [8] Association between smoking status and the efficacy and safety of tofacitinib in patients with Ulcerative Colitis: Data from the tofacitinib clinical programme
    Rubin, D. T.
    Torres, J.
    Regueiro, M.
    Reinisch, W.
    Prideaux, L.
    Kotze, P. G.
    Tan, F. H.
    Gardiner, S.
    Mundayat, R.
    Cadatal, M. J.
    Ng, S. C.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I506 - I507
  • [9] Association between smoking status and the efficacy and safety of tofacitinib in patients with Ulcerative Colitis: Data from the tofacitinib clinical programme
    Rubin, D. T.
    Torres, J.
    Regueiro, M.
    Reinisch, W.
    Prideaux, L.
    Kotze, P. G.
    Tan, F. H.
    Gardiner, S.
    Mundayat, R.
    Cadatal, M. J.
    Ng, S. C.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I506 - I507
  • [10] Pharmacology and safety of tofacitinib in ulcerative colitis
    Lopez-Sanroman, Antonio
    Esplugues, Juan, V
    Domenech, Eugeni
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2021, 44 (01): : 39 - 48
12345